For a patient whose blood pressure remains uncontrolled on amlodipine, losartan, and hydrochlorothiazide (Amlozaar H), which additional medication should be added?

Add Spironolactone as Your Next Agent

For a patient with uncontrolled blood pressure on amlodipine, losartan, and hydrochlorothiazide (Amlozaar H), add spironolactone as the fourth-line agent. This is the strongest evidence-based recommendation for resistant hypertension 1, 2.

Why Spironolactone is the Clear Choice

Both the 2025 AHA/ACC guidelines and 2024 ESC guidelines explicitly recommend adding a mineralocorticoid receptor antagonist (MRA), specifically spironolactone, when blood pressure remains uncontrolled on a three-drug combination of ACE inhibitor/ARB + calcium channel blocker + thiazide diuretic 1, 2.

Key Requirements Before Adding Spironolactone:

• Check eGFR: Must be ≥45 mL/min/1.73 m² per AHA/ACC guidelines 1
• Check potassium levels: Ensure no hyperkalemia before starting
• Verify medication adherence: Rule out pseudo-resistant hypertension
• Review all medications: Remove any drugs that interfere with BP control (NSAIDs, decongestants, etc.) 1

Dosing Strategy:

Start with low-dose spironolactone (typically 12.5-25 mg daily) 2. The ESC guidelines specifically emphasize "low-dose" to minimize side effects while maintaining efficacy.

Alternative Options if Spironolactone Cannot Be Used

If spironolactone is not tolerated or contraindicated (hyperkalemia, renal dysfunction with eGFR <45, gynecomastia), consider these alternatives in order 1, 2:

1. Eplerenone - Another MRA with fewer hormonal side effects
2. Amiloride - Potassium-sparing diuretic (though less effective than enalapril in one study 3)
3. Beta-blocker (bisoprolol preferred per ESC) - if not already indicated 2
4. Alpha-blocker (doxazosin) 2
5. Centrally acting agents 1, 2

Critical Pitfalls to Avoid

Do not combine two RAS blockers (ACE inhibitor + ARB) - this is explicitly contraindicated 2. Since your patient is already on losartan (ARB), do not add an ACE inhibitor.

Before labeling as true resistant hypertension, ensure:

• Patient is actually taking medications (check pharmacy refill records)
• Proper BP measurement technique (out-of-office BP monitoring preferred)
• No white coat hypertension
• No interfering medications or substances (NSAIDs, alcohol, sodium excess)
• Screen for secondary causes if not already done 1

Expected Outcomes

The addition of spironolactone to your patient's existing three-drug regimen should provide significant additional BP reduction. The 2025 AHA/ACC guidelines note that patients with resistant hypertension have at least 50% higher risk of MI, stroke, and cardiovascular death 1, making aggressive treatment essential.

Monitor potassium and renal function within 1-2 weeks after starting spironolactone, then periodically thereafter, as hyperkalemia is the main safety concern with MRA therapy.